Hepatocellular carcinoma: Diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis

Radiology

Volumn 275, Issue 1, 2015, Pages 97-109

  Lee, Yoon Jin ^a   Lee, Jeong Min ^b   Lee, Ji Sung ^c   Lee, Hwa Young ^d   Park, Bo Hyun ^d   Kim, Young Hoon ^a   Han, Joon Koo ^b   Choi, Byung Ihn ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GADOXETIC ACID; CONTRAST MEDIUM;

ARTICLE; CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARD; SYSTEMATIC REVIEW; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; RADIOGRAPHY;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926464893     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140690     Document Type: Article

References (60)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893-2917.
2. Gomez EV, Rodriguez YS, Bertot LC, et al. The natural history of compensated HCVrelated cirrhosis: a prospective long-term study. J Hepatol 2013;58(3):434-444.
3. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30(1):3-16.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127 (5 Suppl 1):S35-S50.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-1917.
6. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245-1255.
7. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-1022.
8. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16(3):262-278.
9. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47(1):97-104.
10. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-sec-tion multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010;256(3):806-816.
11. Khalili K, Kim TK, Jang HJ, et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011;54(4):723-728.
12. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101(3):513-523.
13. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 1997;350(9072):185-186.
14. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529-536.
15. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8(2):239-251.
16. Dwamena BA. Midas: a program for metaanalytical integration of diagnostic accuracy studies in Stata. Ann Arbor, Mich: Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, 2007.
17. Harbord R, Whiting P. metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009;9(2):211-229.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539-1558.
19. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10(1):101-129.
20. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10(11):1665-1677.
21. Addley HC, Griffin N, Shaw AS, et al. Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation. Clin Radiol 2011;66(4):349-356.
22. Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOBDTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol 2011;80(2):310-315.
23. Baek CK, Choi JY, Kim KA, et al. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol 2012;67(2):148-156.
24. De Lédinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? a prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002;14(2):159-165.
25. Denecke T, Grieser C, Fröling V, et al. Multislice computed tomography using a triplephase contrast protocol for preoperative assessment of hepatic tumor load in patients with hepatocellular carcinoma before liver transplantation. Transpl Int 2009;22(4):395-402.
26. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPAenhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triplephase multidetector CT imaging. J Magn Reson Imaging 2011;34(1):69-78.
27. Hirakawa M, Yoshimitsu K, Irie H, et al. Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology. Japanese journal of radiology. 2011;29(2):129-137.
28. Kim SH, Kim SH, Lee J, et al. Gadoxetic acidenhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192(6):1675-1681.
29. Lee DH, Kim SH, Lee JM, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on Milan criteria: correlation with histopathological findings. Invest Radiol 2009;44(6):311-321.
30. Luca A, Caruso S, Milazzo M, et al. Multidetectorrow computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol 2010;20(4):898-907.
31. Luo W, Numata K, Morimoto M, et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agentenhanced US versus 3D contrast-enhanced multidetector CT. Radiology 2009;251(1):287-295.
32. Maetani YS, Ueda M, Haga H, et al. Hepatocellular carcinoma in patients undergoing living-donor liver transplantation: accuracy of multidetector computed tomography by viewing images on digital monitors. Intervirology 2008;51(Suppl 1):46-51.
33. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59(5):638-644.
34. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011;261(3):834-844.
35. Sersté T, Barrau V, Ozenne V, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology 2012;55(3):800-806.
36. Xiao XG, Han X, Shan WD, Li AY. Multislice CT angiography by triple-phase enhancement in preoperative evaluation of hepatocellular carcinoma. Chin Med J (Engl) 2005;118(10):844-849.
37. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U. S. multicenter phase III study. Radiology 2005;237(1):89-98.
38. Böhm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130(5):266-272.
39. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003;38(4):1034-1042.
40. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003;228(3):719-726.
41. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002;222(1):73-80.
42. Ward J, Guthrie JA, Scott DJ, et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000;216(1):154-162.
43. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acidenhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255(2):459-466.
44. Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumineenhanced MRI. AJR Am J Roentgenol 2008;191(2):529-536.
45. Giorgio A, De Stefano G, Coppola C, et al. Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Res 2007;27(6C):4263-4269.
46. Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006;239(2):438-447.
47. Lauenstein TC, Salman K, Morreira R, et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol 2007;189(3):663-670.
48. Becker-Weidman DJ, Kalb B, Sharma P, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadoliniumenhanced MR imaging.comparison to prior same-center results after MR systems improvements. Radiology 2011;261(3):824-833.
49. ∗-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard. J Comput Assist Tomogr 2011;35(6):711-715.
50. Mita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2010;16(33):4187-4192.
51. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr 2010;34(4):506-512.
52. Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, Marrero JA. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 2010;32(2):360-366.
53. Le Moigne F, Durieux M, Bancel B, et al. Impact of diffusion-weighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magn Reson Imaging 2012;30(5):656-665.
54. Park MJ, Kim YK, Lee MW, et al. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264(3):761-770.
55. Park MS, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusionweighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology 2012;56(1):140-148.
56. Rimola J, Forner A, Tremosini S, et al. Noninvasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis: diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 2012;56(6):1317-1323.
57. Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9(2):161-167.
58. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14(4):559-578.
59. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 2003;180(4):1007-1014.
60. Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. London, England: BMJ Books, 2001;248-282.